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Abstract
The aim was to empirically test the tenets of Earnshaw and Chaudoir’s HIV stigma framework and its potential covariates 
for persons living with HIV in Sweden. Partial least squares structural equation modelling was used on survey data from 173 
persons living with HIV in Sweden. Experiencing stigma was reported to a higher extent by younger persons and by women 
who had migrated to Sweden. As expected, anticipated stigma was related to lower Physical functioning, and internalized 
stigma to lower Emotional wellbeing. In contrast to that hypothesized by the HIV stigma framework, enacted stigma was not 
related to Physical functioning and no relationships were found between HIV-related stigma and antiretroviral adherence. 
These results indicate that the HIV stigma framework may need to be revised for contexts where a very high proportion of 
persons living with HIV are diagnosed and under efficient treatment.
Keywords HIV stigma framework · HIV-related stigma · Health-related quality of life · Adherence to ART 
Resumen
El objetivo fue probar empíricamente los postulados del marco teórico del estigma del VIH (HSF) de Earnshaw y Chaudoir 
y sus covariables para personas con el VIH en Suecia. Se empleó el modelo de ecuaciones estructurales con la escala PLS 
(Partial least squares), sobre datos obtenidos en 173 encuestas a personas con el VIH en Suecia. El estigma experimentado 
fue más frecuente en jóvenes y mujeres emigrantes. Como se esperaba, el estigma anticipado estuvo asociado a bajo fun-
cionamiento físico, y el internalizado a bajo bienestar emocional. En contra de las hipótesis del HSF, el estigma declarado 
no tuvo relación con el funcionamiento físico y no se encontró ninguna relación entre el estigma relacionado con el VIH y 
la adherencia a los antirretrovirales. Estos resultados sugieren que el marco teórico HSF debería ser ajustado para contextos 
en los que un alto porcentaje de las personas con el VIH están diagnosticadas y bajo tratamiento eficaz.
Background
Feeling stigmatized due to living with HIV has been shown 
to be related to poor quality of life in different cultures 
[1–4]. Since the beginning of the HIV pandemic, experi-
encing stigma related to HIV has also been shown to be a 
barrier to treatment and prevention [5, 6]. Several theoretical 
frameworks have been presented for how HIV-related stigma 
manifests and operates [7–12]. One of the most cited frame-
works, the HIV stigma framework by Earnshaw and Chau-
doir [10], aims to capture the effects of HIV-related stigma 
on an individual level. The HIV stigma framework [10] 
covers mechanisms and outcomes of HIV-related stigma for 
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individuals living with HIV and individuals who are (known 
or assumed to be) uninfected. The present study focuses on 
the part of the framework that addresses individuals living 
with HIV. According to the HIV stigma framework, the 
social phenomenon of HIV stigma impacts persons living 
with HIV through three different mechanisms: (1) Enacted 
stigma involving experiences of prejudice, marginalization 
and negative treatment by others due to one’s HIV, (2) Antic-
ipated stigma involving expectations of enacted stigma and 
(3) Internalized stigma referring to when the stereotypes, 
labels and beliefs that constitute the stigma are endorsed 
and applied to oneself by the stigmatized person. The HIV 
stigma framework stresses the importance of differentiating 
between stigma mechanisms during measurement, since they 
may relate differently to health-related outcomes for persons 
living with HIV. When the framework was first described, 
the three stigma mechanisms were hypothesized to be related 
differently to psychological, behavioral and health outcomes 
for persons living with HIV [10]. In Earnshaw et al.’s [13] 
empirical evaluations of the HIV stigma framework for per-
sons living with HIV, these outcomes of HIV-related stigma 
were specified as physical, behavioral and affective health 
and wellbeing. It has been suggested that enacted and antic-
ipated stigma affects the individual’s physical health and 
wellbeing, since enacted and anticipated stigma can be a 
stressful experience, a stress considered so severe that physi-
cal health may be affected [13–15]. Anticipated stigma was 
thought to have consequences for behavioral health and well-
being, since the individual may, for example, avoid medical 
care visits and skip medicine doses for fear of disclosing 
their HIV-status [5]. Internalized stigma was also proposed 
to influence behavioral health in the form of adherence to 
therapy due to feelings of not deserving treatment for their 
HIV infection or not deserving to feel well [5]. Internalized 
stigma could result in the individual having negative feelings 
about him or herself, e.g. feeling “less than” others, and has 
been associated with affective consequences such as mental 
health problems, for example depression [16]. It was there-
fore hypothesized that internalized stigma impacts affective 
health and wellbeing [13].
Isolated parts of the framework have been further 
explored [6, 17–22]. Anticipated stigma has been shown 
to be related to physical health in the form of more HIV 
symptoms among people living with HIV in the US, and 
social support has been found to buffer this relationship [17]. 
An extensive review of the literature has linked HIV-related 
stigma to behavioral health in the form of low antiretroviral 
adherence [6]. More specifically, internalized stigma has 
been shown to be related to lower antiretroviral adherence 
among people living with HIV in a US context [18] and 
also to be related to affective health in the form of depres-
sion among men who have sex with men in China [19]. 
Furthermore, the relationship between internalized stigma 
and behavioral health (low antiretroviral adherence) has 
been shown to be mediated by social support and depres-
sive symptoms [21]. Internalized stigma has also been found 
to be related to engagement in care (mediated by HIV dis-
closure) and to higher virus levels for persons living with 
HIV in Italy [22]. The HIV stigma framework has also 
been expanded into a model where enacted and internalized 
stigma is related to perceived community stigma [20]. Per-
ceived community stigma was found to be related to lower 
self-esteem (affective health) and lower antiretroviral adher-
ence (behavioral health), relationships that were mediated by 
internalized stigma [20]. However, the original HIV stigma 
framework for persons living with HIV has, to our knowl-
edge, only been evaluated empirically once, where empirical 
support for all the hypothesized relationships were found, 
except for the relationship between anticipated stigma and 
adherence [13].
According to Deacon [7] theories should constantly be 
reassessed in relation to empirical evidence. Since isolated 
parts of the framework have only been tested in a limited 
amount of studies [6, 17–22] and the entire original frame-
work has only been tested once, and then only in a US con-
text with a high rate of persons with HIV symptoms [13] 
(indicating suboptimal access to efficient treatment), we 
conclude that there is a lack of knowledge regarding the 
validity of the framework for different populations as well 
as in contexts with high access to contemporary antiretro-
viral treatment. Furthermore, since the stigma mechanisms 
are correlated [13], we argue that it is of significance to test 
all hypothesized relationships in the framework simultane-
ously. The present work is therefore an attempt to contribute 
to the theory building regarding factors that correlate with 
HIV-related stigma for individuals living with HIV. Our 
hypothesis was that the framework is valid for persons liv-
ing with HIV in contexts other than those previously tested, 
including a context with very high access to antiretroviral 
therapy. This hypothesis was tested empirically with data 
collected from persons living with HIV in Sweden, where 
antiretroviral treatment is available to all, free of charge and 
where all UNAIDS/WHO 90-90-90 goals are met [23]. The 
aim of the present work was to test the tenets of the HIV 
stigma framework and its potential covariates for persons 
living with HIV in Sweden.
Methods
Procedure and Respondents
Data for this study was drawn from a cross-sectional survey 
of persons living with HIV recruited from the Department 
of Infectious Diseases at the Karolinska University Hospital 
in Stockholm, Sweden. The recruitment process for the data 
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collection is described in detail elsewhere [24]. Inclusion 
criteria were (1) aged 18 years or older, (2) not being on 
their first appointment at the clinic and (3) being able to 
understand and complete the questionnaire in either Swed-
ish, English or with assistance from a professional trans-
lator. Eligible respondents were included consecutively 
after signing informed consent. The study was approved 
by the Regional Ethical Review Board of Stockholm, Swe-
den (2008/1:12 with amendment 2013/335-32). Out of 360 
potential respondents, 193 (54%) agreed to participate and 
returned a questionnaire. Of these, 132 returned a fully com-
pleted questionnaire (minimum response rate 37%) and a 
further 41 completed enough items for subscale scores to 
be calculated for all variables included in the path model. 
Responses from a total of 173 participants (48%) therefore 
constituted the sample in this study.
Operationalization of Concepts in the HIV Stigma 
Framework
In the present study, a path model was specified based on 
the HIV stigma framework (Fig. 1). Alternative measures 
were used compared to when the model was tested by Earn-
shaw et al. [13]. The measures used in the present work are 
summarized in Table 1, with corresponding concepts in the 
HIV stigma framework. The measures used are described in 
detail in the Measures’ section below but in brief: enacted 
stigma was operationalized by Personalized stigma, antici-
pated stigma was operationalized by Disclosure concerns 
and Concerns about public attitudes and internalized stigma 
was operationalized by Negative self-image [25]. Physical 
health and wellbeing were assessed using self-reported phys-
ical functioning [26]. Behavioral health and wellbeing were 
measured by antiretroviral adherence, assessed through HIV 
viral load (VL) as a pseudo marker (HIV RNA < 50 cop-
ies/ml). Affective health and wellbeing were assessed using 
self-reported emotional wellbeing [26]. Age and a combined 
measure of gender and origin were included in the model 
Fig. 1  A hypothesized path 
model of the relationships 
between HIV stigma mecha-
nisms and measures of health 
and wellbeing for persons living 
with HIV in Sweden based on 
Earnshaw and Chaudoir’s [10] 
HIV stigma framework, as 
further elaborated in Earnshaw 
et al. [13]. Age and a combined 
measure of gender and origin 
were included as potential 
covariates, hypothesized to 
be correlated to HIV stigma 
mechanisms and related to 
measures of health and wellbe-
ing (presented schematically in 
this figure)
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as covariates to evaluate the accuracy of the framework for 
different groups.
Measures
HIV Stigma Mechanisms
HIV stigma mechanisms were measured using the Swed-
ish version of the HIV stigma scale [24] previously trans-
lated and adapted from the English HIV stigma scale [25]. 
The Swedish version of the HIV stigma scale is a 39-item 
scale that measures four dimensions of HIV-related stigma 
matching the three stigma mechanisms in the HIV stigma 
framework: the dimension Personalized stigma (16 items) 
measures enacted stigma, Concerns about public attitudes 
(7 items) and Disclosure concerns (8 items) measure antici-
pated stigma and Negative self-image (8 items) measures 
internalized stigma. All items are statements that the partici-
pant can agree or disagree with on a four-point Likert scale 
(1 = strongly disagree, 2 = disagree, 3 = agree, 4 = strongly 
agree). Scores from each item in a dimension were sum-
marized to a subscale score, with higher scores reflecting 
more stigma [24]. Missing values were imputed where 
respondents had completed more than 50% of the items for 
a subscale using multiple Bayesian imputation [27] over five 
datasets in AMOS.
Physical Health and Wellbeing
The Physical functioning scale (7 items) from The Swed-
ish Health-Related Quality of Life survey (Swed-Qual) 
[26], a Swedish health-related quality of life instrument, 
was used as a measure of physical health and wellbeing, 
i.e. the extent to which the health of the participant inter-
feres with his or her ability to perform physical activities. 
Items were answered on a four-point Likert scale; the answer 
to each item was transformed into scores from 0-100. The 
mean score of the seven items belonging to the scale then 
Table 1  Concepts in the HIV stigma framework and corresponding measures used in the present study
a Subscales of the HIV stigma scale [25]
b Subscales of the SwedQual [26]
Concept in the HIV stigma 
framework
Measure used in the present 
study (n items)
Brief description of measure 
used in the present study
Sample item Cronbach’s alpha
Enacted stigma Personalized  stigmaa (16) Perceived consequences of 
other people knowing about 
one’s HIV [25]
People have physically 
backed away from me when 
they learn I have HIV
0.957
Anticipated stigma Disclosure  concernsa (8) Concerns about disclosing 
one’s HIV status to others 
[25]
I worry that people may 
judge me when they learn I 
have HIV
0.876
Concerns with public 
 attitudesa (7)
Concerns about other peo-
ple’s opinion about HIV 
[25]
Since learning I have HIV, 
I worry about people dis-
criminating against me
0.875
Internalized stigma Negative self-imagea (8) Feeling of being unclean, not 
as good as others because of 
HIV [25]
Having HIV in my body is 
disgusting to me
0.884
Physical health and wellbeing Physical  functioningb (7) To what extent one’s health 
interferes with ability to 
perform physical activities 
[26]
Is your health today good 
enough that you can do the 
following activities?
Strenuous activities, e.g., 
heavy manual work, strenu-
ous sports
0.904
Behavioral health and wellbe-
ing
Antiretroviral adherence Non-adherence as defined by 
one VL > 150 copies/ml 
or two or more consecutive 
VL > 50 copies/ml within 
the last 2 years of the condi-
tion with treatment ongoing 
at least 6 months prior to 
the evaluation period
Affective health and wellbe-
ing
Emotional wellbeing: nega-
tive  effectb (6)
Negative feelings during the 
last week [26]
I have felt sad 0.896
Emotional wellbeing: positive 
 effectb (6)
Positive feelings during the 
last week [26]
I have felt liked 0.844
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constituted the Physical functioning scale score, with higher 
scores indicating better physical functioning [26].
Behavioral Health and Wellbeing
A measure of HIV VL was used as a pseudo marker of 
respondents’ adherence to antiretroviral treatment, which 
represents behavioral health and wellbeing. High concord-
ance between adherence to antiretroviral treatment and VL 
has been shown for persons living with HIV in Sweden, 
with 94% of patients who reported optimal adherence hav-
ing a VL < 50 HIV RNA copies/ml [28]. Respondents’ VL 
test results were obtained from the medical records via 
the National quality assurance registry InfCare HIV [28], 
which is an integrated part of the medical records, and 
were examined retrospectively for the previous 2 years. 
Respondents who had one VL > 150 copies/ml or two 
or more consecutive VL > 50 copies/ml within the past 
2 years of having the condition, with treatment ongoing 
for at least 6 months prior to the evaluation period, were 
classified as non-adherent, all other respondents were con-
sidered as adherent.
Emotional Health and Wellbeing
Emotional health and wellbeing was measured with the sub-
scales Emotional wellbeing: negative effect (6 items) and 
Emotional wellbeing: positive effect (6 items) from Swed-
Qual [26]. Items were answered on a five-point Likert scale 
and scored in the same way as described for Physical func-
tioning above. Higher scores indicate better emotional well-
being for both scales. Lower scores for Emotional wellbeing: 
negative effect indicate that the respondent has felt nervous, 
tense, down, impatient, sad or annoyed during the past week 
whilst higher scores for Emotional wellbeing: positive effect 
indicate that the respondent has been a happy person who 
has felt liked, emotionally in harmony, and has had much to 
look forward to during the past week [26].
Sociodemographic and Clinical Variables
In the survey, respondents were also asked to report gender, 
age and country of birth. Information regarding years since 
diagnosis and route of HIV transmission for each partici-
pant was retrieved from the medical records via InfCare HIV 
[29]. Route of HIV transmission was classified into homo/
bisexual, heterosexual, intravenous drug use or other.
Statistical Analysis
Gender, age, country of birth and route of HIV transmis-
sion of the respondents were compared to non-respondents 
and to the total population of persons living with HIV in 
Sweden [29] to evaluate the validity of the sample used in 
the present study. Furthermore, gender, age and CD4 counts 
of the respondents were compared to published data from 
Earnshaw et al.’s [13] previous evaluation of the HIV stigma 
framework to evaluate the presence of any significant dif-
ferences between the samples. T-tests were conducted for 
continuous and χ2-tests for categorical variables.
The hypothesized model of Earnshaw and Chaudoir’s 
[10] HIV stigma framework (Fig. 1) was tested using par-
tial least squares structural equation modelling (PLS-SEM) 
with bootstrapping, in smartPLS3 [30]. Since missing data 
for the stigma scales were imputed with multiple imputa-
tions over five datasets, the bootstrapping PLS-SEM was 
replicated five times; estimates were then averaged. The 
soft modeling technique PLS-SEM was chosen due to the 
relatively small sample size together with different levels of 
data among the variables (binary, ordinal, continuous, with 
a majority of variables showing a non-normal distribution) 
[31]. Significance level was set to ≤ 0.05 (two tailed). Boot-
strapping with 5000 replications in smartPLS3 was used to 
assess whether direct effects were significantly separated 
from zero (no significant change was chosen as method for 
Table 2  Sociodemographic and clinical characteristics of the sample 
of persons living with HIV in Sweden, n = 173
a Non-adherence as defined by one VL  >  150 copies/ml or two or 
more consecutive VL  >  50 copies/ml within the last 2  years of the 
condition with treatment ongoing at least 6 months prior to the evalu-
ation period
Characteristic N (%) Mean (SD) Range
Age 48.1 (11.4) 19–83
Years since HIV diagnosis 12.0 (8.0) 0–29
Gender
 Female 74 (43)
 Male 99 (57)
Country of birth
 Sweden 84 (49)
 Not Sweden 89 (51)
Education
 Elementary school 32 (19)
 High school/secondary school 66 (38)
 College or university degree 63 (36)
 Other 12 (7)
Route of transmission
 Heterosexual 99 (57)
 Homo/bisexual 51 (30)
 Intravenous drug use 12 (7)
 Other 11 (6)
Non-adherent to antiretroviral 
 treatmenta
16 (9)
CD4 count < 200 × 106 cells/ml 7 (4)
On antiretroviral treatment 165 (95%)
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dealing with significant changes during the bootstrap itera-
tions) [31]. Significance for Pearson correlations coefficients 
were assessed in R statistics [32] with package Hmisc [33]. 
Standardized direct effects were interpreted as effect sizes 
according to guidelines for Cohens d, where values of 
0.2–0.49 are interpreted as small, 0.5–0.79 as medium, and 
values exceeding 0.8 as large [34]. Effect sizes of correla-
tions ranging between 0.1–0.29, 0.3–0.49 and > 0.5 were 
interpreted as small, medium and large respectively [34].
Results
Respondents
Participant characteristics are presented in Table 2. Of the 
173 respondents, 43% were female and 51% were born in 
countries other than Sweden. Respondent ages ranged from 
19 to 83 years and the mean age was 48.1 years (SD 11.4). 
The route of HIV transmission was heterosexual in 57% of 
the participants, homo/bisexual in 30%, intravenous drug use 
in 7% and other in 6%. The mean time since HIV diagnosis 
was 12 years (SD 8.0), 9% were classified as non-adherent 
and 4% had a CD4 count less than 200 × 106 cells/ml. The 
characteristics of the sample (n = 173) were compared to 
the characteristics of the population of people living with 
HIV in Sweden and no statistically significant difference 
was found regarding gender (43% female vs. expected 38% 
(28), χ2 = 1.67, df 1, p = 0.20), path of transmission (57% 
heterosexual, 30% homo/bisexual, 7% intravenous drug use 
and 6% other vs. expected 50, 31 , 7 and 12% (28), χ2 = 6.53, 
df 3, p = 0.09) and adherence (9% non-adherent vs. expected 
8% (28), χ2 = 0.366, df 1, p = 0.545). The sample had an 
underrepresentation of persons born in countries other 
than Sweden (51% vs. expected 59% (28), χ2 = 4.08, df 1, 
p < 0.05). Compared to eligible persons who declined to 
participate or who were excluded for other reasons, included 
participants had a statistically significant lower rate of per-
sons born in countries other than Sweden (51% vs. expected 
68%, χ2 = 21.95, p < 0.001) and a significantly lower rate 
of persons with a heterosexual route of HIV transmission 
(57% vs expected 70% (29), χ2 = 28.01, p < 0.001). Com-
pared to the sample used by Earnshaw et al. [13] the Swedish 
sample had a lower rate of persons with CD4 counts below 
200 × 106 cells/ml (4% vs. 20% in Earnshaw et al. [13], 
χ2 = 27.52, p < 0.001).
Descriptive statistics for the HIV stigma scale are pre-
sented in Table 3.
Testing the HIV Stigma Framework
Hypothesized Paths
Three out of eight hypothesized paths in the tested model 
had effects that were statistically significant, Fig. 2. Stand-
ardized direct effects are presented in Table 4. More antici-
pated stigma was associated with worse physical health 
and wellbeing (measured by Physical functioning), as 
hypothesized. However, this was only true for one of the 
two measures of anticipated stigma, Concerns about public 
attitudes, not for Disclosure concerns. As expected, Internal-
ized stigma (measured by Negative self-image) was associ-
ated with lower affective health and wellbeing (measured 
by Emotional wellbeing, both positive and negative effects). 
The effect sizes of these relationships were small. In con-
trast to that hypothesized in the model, Enacted stigma 
(measured by Personalized stigma) had no relationship to 
physical health and wellbeing (measured by Physical func-
tioning). None of the HIV stigma mechanisms were related 
to behavioural health and wellbeing (measured by antiretro-
viral adherence). Regarding the hypothesized paths between 
covariates and measures of health and wellbeing, an inverse 
relationship was found between age and behavioural health 
and wellbeing (small effect size), indicating that persons that 
are non-adherent are of younger age. No other relationships 
were found between covariates and measures of health and 
wellbeing.
Hypothesized Correlations
Correlation coefficients are presented in Table 5. In line with 
what is hypothesized by the HIV stigma framework, correla-
tions were found between all HIV stigma mechanisms, and 
the scales from the Swed-Qual were also found to intercor-
relate (Fig. 2, Table 4). Correlations between the HIV stigma 
scales were found to have medium to large effect sizes, and 
correlations between Swed-Qual scales small, medium and 
large effect sizes. Regarding the covariates included in the 
model, women born in countries other than Sweden had sig-
nificantly more anticipated stigma (measured by Concerns 
about public attitudes) and inverse relationships were found 
between age and all measures of stigma. Effect sizes of these 
correlations were small.
Table 3  Descriptive statistics of the HIV stigma scale results, for the 
sample of persons living with HIV in Sweden, n = 173
a Possible range of the scales and actual range of respondents’ answers 
are equivalent
Sub scales Rangea Mean score (SD)
Personalized stigma 16–64 35.0 (13.2)
Disclosure concerns 8–32 24.5 (6.0)
Concerns about public attitudes 7–28 18.5 (5.1)
Negative self-image 8–32 17.5 (6.5)
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Discussion
In this article, Earnshaw and Chaudoir’s [10] HIV stigma 
framework for people living with HIV has been tested using 
data collected from persons living with HIV in Sweden, a 
context where all UNAIDS/WHO 90-90-90 goals are met 
[23]. The HIV stigma framework was only partly confirmed 
in this empirical test, indicating that the HIV stigma frame-
work needs to be revised for contexts where a very high pro-
portion of people living with HIV are diagnosed and under 
efficient treatment. As hypothesized in the model, antici-
pated stigma (measured by Concerns about public attitudes) 
was related to lower physical health and wellbeing. Disclo-
sure concerns, also used as a measure of anticipated stigma, 
was not related to physical health and wellbeing, indicating 
that it is not Disclosure concerns themselves that are related 
to lower physical wellbeing, but Concerns about other peo-
ple’s negative opinions about HIV. As also hypothesized, 
internalized stigma (measured by Negative self-image) 
was associated with lower affective health and wellbeing. 
Low behavioral health and wellbeing was only found to be 
inversely related to age and there was no significant rela-
tionship between enacted stigma (measured by Personalized 
stigma) and low physical health and wellbeing. There was 
a lower rate of persons with CD4 counts below 200 × 106 
cells/ml, i.e. there were more individuals whose HIV infec-
tion was in a better state, in the sample used in the present 
study than the sample used in the previous evaluation of 
Fig. 2  Results from the partial least squares structural equation mod-
elling (PLS-SEM) analysis of the hypothesized path model presented 
in Fig.  1, empirically evaluated with self-reported and clinical data 
from persons living with HIV in Sweden. This figure illustrates the 
relationships with further data presented in Tables  4 and 5. The 
model depicts the relationships between measures of HIV stigma 
mechanisms (large boxes to the left), covariates (small boxes) and 
measures of health and wellbeing: Physical functioning, Antiretro-
viral adherence and Emotional wellbeing (boxes to the right). The 
estimates next to each arrow represent correlation coefficients and 
standardized direct effects. Black lines represent relationships that are 
statistically significant at a significance level of p < 0.05. Grey lines 
represent non-significant paths. Estimates for non-significant paths 
regarding covariates are not shown
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the framework [13]. The HIV stigma framework, however, 
proposes to capture health-related effects of stigma for all 
persons living with HIV [10] and our hypothesis was there-
fore that the framework would also be valid for persons 
who are virally suppressed. This hypothesis could not be 
confirmed and a new hypothesis, drawn from our results, 
is that HIV-related stigma may have fewer or alternate out-
comes for persons with good physical health and full access 
to antiretroviral treatment, such as the sample included in 
the present study. The impact that HIV-related stigma can 
Table 4  Standardized direct 
effects for hypothesized paths 
in the HIV stigma framework 
for persons living with HIV 
(n = 173) calculated using 
partial least square structural 
equation modelling (PLS-SEM) 
with bootstrapping
a 0, Adherent; 1, non-adherent
b 0, other; 1, female, migrated to Sweden
Hypothesized path Sample Mean SD T value p value
Personalized stigma—physical functioning − 0.08 0.11 0.77 0.47
Disclosure concerns—physical functioning 0.14 0.09 1.62 0.11
Concerns about public attitudes—physical functioning − 0.33 0.11 3.07 < 0.05
Disclosure concerns—antiretroviral  adherencea − 0.15 0.11 1.11 0.31
Concerns about public attitudes—antiretroviral  adherencea < 0.01 0.12 0.16 0.87
Negative self-image—antiretroviral  adherencea − 0.05 0.11 0.49 0.63
Negative self-image—emotional wellbeing: positive effect − 0.21 0.07 2.97 < 0.05
Negative self-image—emotional wellbeing: negative effect − 0.45 0.07 6.90 < 0.05
Age—physical functioning − 0.08 0.08 1.03 0.31
Age—antiretroviral  adherencea − 0.21 0.07 3.12 < 0.05
Age—emotional wellbeing: positive effect − 0.03 0.06 0.53 0.60
Age—emotional wellbeing: negative effect 0.01 0.07 0.09 0.93
Gender and  originb—physical functioning − 0.07 0.08 0.84 0.40
Gender and  originb—antiretroviral  adherencea 0.12 0.09 1.28 0.20
Gender and  originb—emotional wellbeing: positive effect 0.09 0.07 1.46 0.15
Gender and  originb—emotional wellbeing: negative effect 0.06 0.07 0.89 0.37
Table 5  Pearson correlation 
coefficients between variables 
in the HIV stigma framework 
for persons living with HIV 
(n = 173)
Hypothesized path Correlation 
coefficient
p value
Personalized stigma—disclosure concerns 0.39 < 0.05
Personalized stigma—concerns about public attitudes 0.65 < 0.05
Personalized stigma—negative self-image 0.51 < 0.05
Disclosure concerns—concerns about public attitudes 0.58 < 0.05
Disclosure concerns—negative self-image 0.54 < 0.05
Concerns about public attitudes—negative self-image 0.58 < 0.05
Personalized stigma—age − 0.16 < 0.05
Personalized stigma—gender and origin 0.08 0.27
Disclosure concerns—age − 0.20 < 0.05
Disclosure concerns—gender and origin 0.08 0.33
Concerns about public attitudes—age − 0.26 < 0.05
Concerns about public attitudes—gender and origin 0.21 < 0.05
Negative self-image—age − 0.29 < 0.05
Negative self-image—gender and origin 0.11 0.17
Age—gender and origin − 0.30 < 0.05
Physical functioning—antiretroviral adherence < 0.01 0.28
Physical functioning—emotional wellbeing: positive effect 0.44 < 0.05
Physical functioning—emotional wellbeing: negative effect 0.30 < 0.05
Antiretroviral adherence—emotional wellbeing: positive effect − 0.08 0.79
Antiretroviral adherence—emotional wellbeing: negative effect 0.02 0.06
Emotional wellbeing: positive effect—emotional wellbeing: negative effect 0.56 < 0.05
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have on the lives of persons living with HIV who have full 
access to antiretroviral treatment and high treatment adher-
ence needs to be further explored in future research, which 
could lead to a revision of the HIV stigma framework for 
persons living with HIV.
The analysis of the covariates showed that women born in 
countries other than Sweden experienced anticipated stigma 
to a higher extent, and that younger age was related to higher 
levels of anticipated and internalized stigma. However, the 
effect size of these relationships was small. Earlier research 
shows contradictory results regarding whether the levels of 
HIV-related stigma differ with gender, origin and age. In a 
meta-analysis of health and demographic correlates to HIV-
related stigma in a north-American context [2], only two of 
the articles included explored differences related to ethnic-
ity, with contradictory results. In the same meta-analysis, 
differences related to gender were explored in three studies, 
with no statistically significant difference found. However, 
younger age was found to be related to higher levels of HIV-
related stigma [2], in line with the results of the present 
study. Regarding the results of the present study, with a 
majority of respondents being under successful treatment, 
we want to emphasize that the effect of the covariates were 
small, indicating that persons experiencing high levels of 
stigma mechanisms may be found in all groups regardless 
of gender, origin and age.
Physical health and wellbeing (measured by Physical 
functioning) had, in contrast to earlier research, no relation 
to enacted stigma. To experience enacted stigma related to 
one’s HIV has earlier been shown to be a stressful experi-
ence that via neuroendocrine and sympathetic nervous sys-
tem pathways impacts physical health [14, 15]. In the sample 
used in the present study, very few persons had CD4 levels 
under 200 × 106 cells/ml or viral loads > 150 copies/ml. We 
therefore chose Physical functioning as a measure of physi-
cal health and wellbeing, since this variable had a larger 
variance, but this measure was not related to enacted stigma. 
Social support and community support have earlier been 
shown to buffer the association between anticipated stigma, 
stress and HIV symptoms, but not the association between 
enacted stigma, stress and HIV symptoms [17]. Further 
research is needed to explore if such factors have functioned 
as mediators and buffered the relationship between enacted 
stigma and physical health and wellbeing in a Swedish con-
text. We did, however, find a statically significant relation-
ship between physical health and wellbeing and anticipated 
stigma, which could possibly be explained by anticipated 
stigma being a stressful experience. Earlier research has also 
shown that people living with chronic illnesses who antici-
pate stigma were less likely to access care [35], which may 
also be a possible explanation to lower physical health and 
wellbeing for persons who anticipate stigma.
Behavioral health and wellbeing (as measured by VL 
as a marker of antiretroviral adherence) had no relation to 
HIV stigma mechanisms, which stands in contrast to earlier 
research where substantial empirical evidence has linked 
stigma to adherence difficulties [6, 18, 21] and less access 
to care [35], also in a Swedish context [36]. In Sweden, all 
persons diagnosed with HIV are obliged by the Swedish 
Communicable Diseases Act to avoid lost contacts with 
care and each individual is linked to a specialized HIV care 
center with quality assured care and treatment [23]; this 
may counteract negative effects of HIV stigma on behavio-
ral health. There is also a possibility that respondents in the 
sample experience dimensions of stigma, e.g. layered stigma 
[37] not covered by the HIV stigma scale. Similarly, the 
hypothesized path between anticipated stigma and behavio-
ral health and wellbeing was not confirmed when the HIV 
stigma framework was tested in an American context, and 
the authors related this to the cross-sectional design of the 
study [13]. The authors reasoned that anticipated stigma 
would have the strongest effect on future behavior, and there-
fore it would be preferable to measure this using a longitu-
dinal design. We disagree with this reasoning and propose 
that anticipated stigma is something that can be a part of 
and affect everyday life. Therefore, a relationship between 
stigma and behavior should show even when investigated 
in a cross-sectional design, although causal relationships 
need to be investigated in longitudinal designs. One study 
has earlier shown that the relationship between HIV-related 
stigma and medical adherence was partially mediated by 
depression [38], something that is not addressed in the HIV 
stigma framework. However, if this mediated relationship 
was accurate in a Swedish context, we would have expected 
a stronger correlation between Emotional wellbeing and 
Antiretroviral adherence.
Affective health and wellbeing was, in line with earlier 
research, related to internalized stigma. Experiencing inter-
nalized stigma was associated both with having felt more 
negative feelings during the past week (negative affect) 
and having felt fewer positive feelings during the past week 
(positive affect). This corresponds to recent research where 
positive and negative affect were shown to mediate a rela-
tion between self-stigma and depression among Chinese men 
who have sex with men [19]. Future research should exam-
ine the relationship between internalized stigma, negative 
and positive affect, and depression in a population with high 
access to antiretroviral treatment.
Although the present study used a cross-sectional design 
and therefore does not provide information about causality 
among hypothesized relationships, we would like to address 
the question about causality in the HIV stigma framework. 
Earnshaw et al. [13] hypothesize causal relationships in 
the HIV stigma framework, where it is implied that higher 
stigma causes lower wellbeing. As shown, persons who 
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anticipate stigma (measured by Concerns about public atti-
tudes) to a higher extent rated lower Physical functioning. 
According to Earnshaw et al. [13], this may be explained 
as a causal relationship where low Physical functioning is 
caused by anticipated stigma among individuals. We propose 
that alternate explanations can be equally valid. A person 
with high Physical functioning could conceal their HIV 
status, which would prevent the individual from experienc-
ing stigma [39], and low Emotional wellbeing could make 
a person more vulnerable to internalized stigma. We there-
fore propose a shift of focus from causal relationships to 
intertwined relationships between HIV-related stigma and 
measures of health and wellbeing.
Implications for Care
When designing care for persons living with HIV it is valu-
able to know if individuals with certain background charac-
teristics risk experiencing more stigma than others or are at 
higher risk for certain consequences of HIV-related stigma. 
Even if the patterns were not strong, the results of the pre-
sent study imply that persons of younger age and women 
born in other countries than Sweden may be more exposed 
to HIV-related stigma. Therefore, in addition to broadly 
focusing stigma-reducing interventions, special resources 
targeting persons of lower age and women born in other 
countries than Sweden may be warranted. Furthermore, 
since the present study, along with earlier research, shows an 
inverse relationship between internalized stigma and emo-
tional wellbeing, identifying and paying special attention to 
persons with internalized stigma may be warranted. Both the 
internalized stigma and the low emotional wellbeing could 
be targeted within a healthcare setting with support from a 
wide spectrum of healthcare professions. Existing cognitive 
and behavioral interventions that target internalized stigma 
have mainly been developed for women [40, 41], which is 
important, however there also seems to be a need for inter-
ventions targeting internalized stigma among men.
Methodological Considerations
We did not use variables that were identical to those used 
when the framework was previously tested [13] and this may 
have affected the results. The areas in the HIV stigma frame-
work that are hypothesized as being affected by HIV stigma 
(physical, behavioral and affective health and wellbeing) are, 
however, broad concepts and measures of health and wellbe-
ing used in the present study match these concepts. In Earn-
shaw and Chaudoir’s [10] review of HIV stigma mechanism 
measurements, the HIV stigma scale [25] was considered 
to measure enacted, anticipated and internalized stigma. 
However, in their empirical test of the HIV stigma frame-
work [13], an alternative measure for anticipated stigma was 
used with items more explicitly phrased about anticipation 
of enacted stigma in the future. In the present study, meas-
ures of disclosure concerns and concerns about public atti-
tudes about HIV were used to measure anticipated stigma. 
These two scales include items both about what respond-
ents anticipate happening in the future if their HIV status 
becomes known and what the respondent thinks the attitudes 
of people in general are regarding those with HIV, which are 
indicators of what would happen to the respondent if his or 
her HIV status became known. The inclusion of sociode-
mographic correlates into the path model rendered a large 
number of tested relationships, thus limiting the number of 
variables that could be included. Dropping the correlates 
could have given the opportunity to turn physical, behavio-
ral and affective health and wellbeing into latent variables, 
measured by several manifest variables, but we prioritized 
the inclusion of sociodemographic correlates considering 
the lack of research concerning how HIV-related stigma 
varies across different sociodemographic backgrounds. 
Future research could examine if HIV-related stigma var-
ies across persons with different paths of transmission. We 
decided against this since the number of persons whose 
route of transmission was intravenous drug use was low in 
this sample. Furthermore, the cross-sectional design pre-
cludes assumptions of causality among hypothesized rela-
tionships. The use of PLS-SEM supports reliability of the 
results, since PLS-SEM is preferred over covariance based 
SEM (CB-SEM) when data is non-normal and the model is 
complex [42]. In the model analyzed in the present study 
comprising 37 free parameters to estimate, a maximum of 
paths directed towards a construct was eight (including cor-
relations as paths), for Personalized stigma. A minimum 
sample size would then preferably be ten times eight [42], 
i.e. a minimum sample size of 80, which is more than dou-
bled in the present study. A diverse sample of respondents 
was included in this study, which we consider a strength, 
since studies that include self-reported data from persons 
living with HIV often use samples that do not reflect the 
population of people living with HIV. Although the rate of 
eligible respondents that declined to participate was high 
(45%), the sample was found to reflect the population char-
acteristics of people living with HIV in Sweden, despite 
an underrepresentation of persons born in countries other 
than Sweden [24]. The persons attending the clinic from 
which the respondents were recruited live predominantly 
in a metropolitan area, which may have had an impact on 
the results. It is unknown if persons living with HIV experi-
ence stigma differently depending on where in the country 
they live. The prevalence of persons with problems with 
antiretroviral adherence is low in Sweden and in the analysis 
this subgroup is small. The results regarding antiretroviral 
nonadherence should therefore be interpreted with caution.
AIDS and Behavior 
1 3
Conclusion
Despite the limitations with regards to sample size pre-
sented, this study deepens the knowledge of how relations 
between stigma mechanisms and measures of health and 
wellbeing may differ depending on extent of access to care 
and treatment. The HIV stigma framework for persons living 
with HIV, that aims to capture effects of HIV-related stigma 
for all people living with HIV, was only partly confirmed in 
a Swedish context where all UNAIDS/WHO 90-90-90 goals 
are met [23]. The results in the present study indicate that 
the HIV stigma framework for persons living with HIV may 
need to be revised for contexts where a very high proportion 
of people living with HIV are diagnosed and under efficient 
treatment.
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